ArticleInternational journal of retina and vitreous2025
"Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema".
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations.Biomedicines · 2026Review
- Research advances in the translational application of anti-VEGF combined with subthreshold micropulse laser therapy for refractory diabetic macular edema.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimChronic Persistent Diabetic Macular Edema can be a clinical challenge. The aim of this study is to assess the outcomes of intravitreal brolucizumab 6 mg/0.05 ml for persistent diabetic macular edema (P-DME) in a real-world clinical setting.
methodsA prospective interventional trial of consecutive patients with P-DME was conducted at a tertiary care center in India. P-DME was defined as edema persisting despite more than three intravitreal anti-VEGF injections or despite a combination of anti-VEGFs, intravitreal steroids and/or laser photocoagulation. The change in visual acuity (VA), central retinal thickness (CRT) and any incidences of adverse effects were analyzed.
results19 eyes of 13 patients received a mean of 3.3 injections at a mean interval of 11.1 weeks. The median VA improved from 0.40 logMAR (20/50) to 0.35 logMAR (20/44) after a mean period of 13 weeks after the last injection, which was statistically significant (p = 0.004). The CRT reduced from 517 microns to 237 microns (p = 0.001). One patient had an episode of intraocular inflammation, which was treated successfully with topical steroids. The same patient again received brolucizumab with no recurrent inflammation.
conclusionsIntravitreal brolucizumab helped improve visual acuity in patients with P-DME and achieved a reduction of 54.1% in the CRT at a longer mean reinjection interval. The rate of intraocular inflammation was 5.2% without any permanent visual impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.